According to the State Food and Drug Administration website, recently, the State Food and Drug Administration approved Conbercept Ophthalmic Injection for the treatment of wet age-related macular degeneration. Age-related macular degeneration (AMD), also known as age-related macular degeneration, is an aging change in the structure of the macula of the retina, caused by irreversible vision loss or loss of vision mainly due to degenerative lesions of the retinal pigment epithelium and retina. The disease is clinically divided into two types: dry (atrophic) AMD and wet (exudative) AMD, which mostly occurs above 45 years of age, and the incidence increases with age. With the accelerated pace of aging in China, the incidence of wet AMD blinding eye disease is on the rise year by year, and is one of the major eye diseases that reduce vision and cause blindness in the elderly. The main pathological manifestation of wet age-related macular degeneration is choroidal pathological neovascular growth. It is believed that VEGF is an essential inducer in both physiological and pathological angiogenesis, and inhibiting the activity of VEGF can effectively control neovascularization. Compazepine Ophthalmic Injection, approved by the State Food and Drug Administration, is a new class I therapeutic biologic drug, which is a recombinant fusion protein of VEGF receptor and human immunoglobulin Fc segment gene, and this drug inhibits endothelial cell proliferation and angiogenesis by binding to vascular endothelial growth factor VEGF, competitively inhibiting the binding of VEGF to the receptor and preventing the activation of VEGF family receptors. It can be used to treat wet age-related macular degeneration. Compazepine Ophthalmic Injection is the first independently developed drug for the treatment of this disease in China, which is of positive significance to solve the accessibility of clinical drugs in China. Compazepine Ophthalmic Injection is administered via intravitreal injection and should be used in qualified hospitals and ophthalmologists. Hospitals should have the relevant instruments and conditions required for the diagnosis and treatment of this disease, and be operated by ophthalmologically qualified physicians who have been trained in intravitreal injection techniques.